AtriCure launches cryoSPHERE+ probe for pain management

AtriCure has introduced the cryoSPHERE+ cryoablation probe to enhance post-operative pain management. This device, part of the cryoICE platform, received 510(K) clearance from the US FDA for temporarily blocking pain by ablating peripheral nerves in adults and intercostal nerves in adolescents.

The cryoSPHERE+ probe, featuring advanced insulation technology, reduces freeze times by 25% compared to its predecessor. It's currently in an extended limited launch phase in the US, with a full rollout planned by the second quarter's end.

Building upon the safety and efficacy of the original cryoSPHERE probe, utilized in over 60,000 procedures since November 2018, the cryoSPHERE+ device minimizes thermal loss, focusing energy at the ball tip for quicker therapeutic temperature attainment. Additionally, its more rigid shaft ensures consistent pressure application during procedures.

This innovation offers efficiency, particularly in performing multiple ablations on a single patient. AtriCure also initiated patient treatment with its AtriClip LAA Exclusion System in the Left Atrial Appendage Exclusion for Stroke Prevention (LeAAPS) clinical study last year.